Results 11 to 20 of about 12,593 (182)

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis [PDF]

European Respiratory Review, 2017
Pirfenidone is one of two approved therapies for the treatment of idiopathic pulmonary fibrosis (IPF). Randomised controlled clinical trials and subsequent post hoc analyses have demonstrated that pirfenidone reduces lung function decline, decreases ...
Lisa H. Lancaster, Joao A. de Andrade, Joseph D. Zibrak, Maria L. Padilla, Carlo Albera, Steven D. Nathan, Marlies S. Wijsenbeek, John L. Stauffer, Klaus-Uwe Kirchgaessler, Ulrich Costabel   +9 more
doaj   +3 more sources

Effect of pirfenidone on wound healing in lung transplant patients

Multidisciplinary Respiratory Medicine, 2018
Background The drug pirfenidone has been shown to slow the progression and decrease mortality of idiopathic pulmonary fibrosis (IPF). Its exact mechanism is unknown, but it likely inhibits pro-fibrotic cytokine transforming growth factor beta, a known ...
Amber Mortensen, Lauren Cherrier, Rajat Walia   +2 more
doaj   +2 more sources

Pirfenidone inhibits fibrosis in foreign body reaction after glaucoma drainage device implantation

Drug Design, Development and Therapy, 2016
Kyoung In Jung, Chan Kee ParkDepartment of Ophthalmology and Visual Science, Seoul St Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South KoreaBackground: The aim of this study was to investigate the antiscarring ...
Jung KI, Park CK
doaj   +1 more source

Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis

Patient Preference and Adherence, 2014
Yoshito Takeda,1 Kazuyuki Tsujino,2 Takashi Kijima,1 Atsushi Kumanogoh1 1Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita, Osaka, Japan; 2Department of Respiratory Medicine, Kinki ...
Takeda Y, Tsujino K, Kijima T, Kumanogoh A   +3 more
doaj   +1 more source

Topical Administration of Pirfenidone Increases Healing of Chronic Diabetic Foot Ulcers: A Randomized Crossover Study [PDF]

Journal of Diabetes Research, 2016
Only 30 percent of chronic diabetic foot ulcers heal after 20 weeks of standard treatment. Pirfenidone is a drug with biological, anti-inflammatory, and antifibrotic effects.
Marcela Janka-Zires, Paloma Almeda-Valdes, Ana Cecilia Uribe-Wiechers, Sonia Citlali Juárez-Comboni, Joel López-Gutiérrez, Jarod Jazek Escobar-Jiménez, Francisco J. Gómez-Pérez   +6 more
doaj   +2 more sources

Systemic pirfenidone treatment fails to mitigate fibrosis and compromises functional recovery in a porcine model of volumetric muscle loss. [PDF]

Exp Physiol
Abstract Repurposing clinically approved antifibrotic agents presents a potential near‐term therapeutic strategy to mitigate the extensive fibrotic scarring that follows severe volumetric muscle loss (VML) injury and inhibits functional recovery. We hypothesized that daily oral administration of pirfenidone, an FDA‐approved antifibrotic, would mitigate
Motherwell JM, Eken O, Hernandez CE, Dearth CL, Goldman SM.   +4 more
europepmc   +2 more sources

Pirfenidone as a novel cardiac protective treatment [PDF]

, 2021
Myocardial fibrosis is a common feature of several heart diseases. The progressive deposition of extracellular matrix due to a persistent injury to cardiomyocytes may trigger a vicious cycle that leads to persistent structural and functional alterations ...
Emdin, Michele, Bayés-Genís, Antoni, Spitaleri, Giosafat, Aimo, Alberto, Panichella, Giorgia, Lupón, Josep   +5 more
core   +2 more sources

Pirfenidone-Loaded Polymeric Micelles as an Effective Mechanotherapeutic to Potentiate Immunotherapy in Mouse Tumor Models

, 2023
Ongoing research is actively exploring the use of immune checkpoint inhibitors to treat solid tumors by inhibiting the PD-1/PD-L1 axis and reactivating the function of cytotoxic T effector cells.
Andreas Anayiotos (11722364), Fotios Mpekris (612841), Horacio Cabral (1359018), Anna Katsioloudi (17587686), Myrofora Panagi (6295370), Antonia Charalambous (9585582), Theodora Krasia-Christoforou (6398498), Marianna Prokopi-Demetriades (17587689), Petri Ch. Papaphilippou (17587677), Chrysovalantis Voutouri (612840), Christina Michael (17587680), Mariyan Marinov Dinev (17587683), Triantafyllos Stylianopoulos (612844)   +12 more
core   +1 more source

Pirfenidone in idiopathic pulmonary fibrosis:expert panel discussion on the management of drug-related adverse events [PDF]

, 2014
Pirfenidone is currently the only approved therapy for idiopathic pulmonary fibrosis, following studies demonstrating that treatment reduces the decline in lung function and improves progression-free survival.
Per M. Hellström, Groves, Richard, Michael Kreuter, Toby M. Maher, Maher, Toby M, Dewint, P. (Pieter), Sarafidis, A. (Alexandre), Vancheri, C. (Carlo), Egan, Jim JJ, Bendstrup, Elisabeth, Maher, T.M. (Toby), Bendstrup, E. (Elisabeth), Sarafidis, Alexandre, Egan, Jim J J, Vancheri, Carlo, Jim J. J. Egan, Costabel, Ulrich, Ferguson, James, Vincent Cottin, Nordlind, K. (Klas), Cottin, V. (Vincent), Hellström, Per M, Maher, Toby M., Carlo Vancheri, Richard Groves, Groves, R. (Richard), Costabel, U., Klas Nordlind, Dewint, Pieter, Nordlind, Klas, Cottin, Vincent, Ulrich Costabel, Ferguson, J.J. (James), Hellström, A.-L., Alexandre Sarafidis, Pieter Dewint, Egan, Jim J. J., Elisabeth Bendstrup, Kreuter, M. (Michael), Maria Molina-Molina, Molina-Molina, M. (Maria), James Ferguson, Kreuter, Michael, Egan, J.J.J. (Jim J.), Molina-Molina, Maria, Hellström, Per M., Hellström, Per M.,   +46 more
core   +1 more source

Pirfenidone treatment of idiopathic pulmonary fibrosis [PDF]

, 2011
Ye Gan1,2, Erica L Herzog2, Richard H Gomer31Department of Medicine, Central South University, Changsha, Hunan, China; 2Department of Medicine, Yale University School of Medicine, New Haven, CT, USA; 3Department of Biology, Texas A&M University ...
Erica L Herzog, Erica Herzog, Richard H Gomer, null Gan, Ye Gan, Richard Gomer   +5 more
core   +1 more source